Study Design of the Global Prospective Hemolytic Disease of the Fetus and Newborn Registry (GERANIUM).
May Lee Tjoa, Ashley Orillion, Raymond Mankoski...
https://pubmed.ncbi.nlm.nih.gov/41862209/Actively Recruiting
Led by Janssen Research & Development, LLC · Updated on 2026-11-03
175
Participants Needed
17
Research Sites
18 weeks
Total Duration
Researchers are conducting a non-interventional study to evaluate the risk of anemia in fetuses and newborns of pregnant individuals who are at risk for hemolytic disease of the fetus and newborn HDFN. HDFN is a condition where incompatible blood types between the pregnant person and their baby cause rapid breakdown of the babys red blood cells before or shortly after birth. This study aims to collect data prospectively to better understand this risk. Pregnant participants at risk for HDFN will be enrolled and will receive standard of care therapy as per local clinical practice without any study treatment provided by the sponsor. Data will be collected during the pregnancy and for two years after birth for the related neonate, infant, or child. Participants will also complete clinical outcome assessments, including patient- and observer-reported outcomes, at specific times throughout follow-up. Participants will be monitored through their pregnancy and the first two years of their childs life. Data collection includes medical records and outcome assessments completed by participants. Researchers will measure outcomes such as the percentage of pregnancies without fetal loss, intrauterine transfusion, hydrops fetalis, or neonatal death up to four weeks after birth or 41 weeks postmenstrual age. Secondary outcomes include the severity of HDFN, timing of first occurrence of certain complications, neonatal morbidity and mortality indices, and number of transfusions during pregnancy.
CONDITIONS
A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry
S
Study Contact
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Janssen Research & Development, LLC
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote) to confirm eligibility and obtain consent
Duration - Up to 24 weeks of pregnancy
Participants receive standard care while medical data about their pregnancy and fetal health is collected. No study treatments are provided by the sponsor during this period.
Data collection visits as part of routine care
Duration - Up to 2 years post-birth
Medical data for the neonate/infant/child is collected for up to two years after birth, including clinical outcome assessments completed by the participant.
Periodic follow-up visits or assessments
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
May Lee Tjoa, Ashley Orillion, Raymond Mankoski...
https://pubmed.ncbi.nlm.nih.gov/41862209/Janssen Research & Development, LLC
Lead Sponsor